Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Other Accumulated Expenses (2022 - 2025)

TriSalus Life Sciences' Other Accumulated Expenses history spans 4 years, with the latest figure at $234000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 38.9% year-over-year to $234000.0; the TTM value through Dec 2025 reached $234000.0, down 38.9%, while the annual FY2025 figure was $234000.0, 38.9% down from the prior year.
  • Other Accumulated Expenses reached $234000.0 in Q4 2025 per TLSIW's latest filing, up from $224000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $427000.0 in Q3 2023 to a low of $142000.0 in Q4 2022.
  • Average Other Accumulated Expenses over 4 years is $302363.6, with a median of $291000.0 recorded in 2024.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 173.94% in 2023, then crashed 38.9% in 2025.
  • A 4-year view of Other Accumulated Expenses shows it stood at $142000.0 in 2022, then surged by 173.94% to $389000.0 in 2023, then fell by 1.54% to $383000.0 in 2024, then plummeted by 38.9% to $234000.0 in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Other Accumulated Expenses are $234000.0 (Q4 2025), $224000.0 (Q3 2025), and $221000.0 (Q2 2025).